Joseph Rahimian, MD
Infectious Disease · New York, NYNPI 1659344653
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,312 of the $16,134 with a category attached, or 88.7%. 32 manufacturers reported payments, led by Gilead at 35.9% of the total. 2025 is the largest year on record at $5,053, 3.8 times the $1,341 reported in 2019. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 646 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Viiv Healthcare Company$4K
- Johnson & Johnson$2K
- AbbVie$1K
- Merck$1K
- Shionogi Inc$394
- plus $1K from 26 others
Across 40 payments — averaging $321.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$13K
What the payments were for
- Consulting fees$1,75011%
- Food & beverage$14,31289%
- Education$730%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 174 | $5,786 |
| Viiv Healthcare Company | 195 | $4,350 |
| Johnson & Johnson | 60 | $1,626 |
| AbbVie(2 entities) | 93 | $1,465 |
| Merck | 52 | $1,176 |
| Shionogi Inc | 15 | $394 |
| Melinta Therapeutics, LLC | 9 | $195 |
| Theratechnologies Inc. | 6 | $135 |
| Hologic Sales And Service, LLC | 3 | $108 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $74 |
| AstraZeneca | 3 | $64 |
| Napo Pharmaceuticals Inc | 3 | $61 |
| Lilly USA, LLC | 2 | $60 |
| Janssen Products, LP | 2 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
| Pfizer | 2 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| EMD Serono, Inc. | 2 | $44 |
| Corium, LLC | 1 | $31 |
| Cleerly, Inc. | 1 | $30 |
| Philips North America LLC | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Shield Therapeutics Inc | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$16,134 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 100 | $435,360 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 38 | $144,640 |
| IsentressRaltegravir Potassium | 72 | $141,284 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 34 | $116,972 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $91,658 |
| TivicayDolutegravir Sodium | 36 | $81,071 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $68,617 |
| PrezcobixDarunavir/Cobicistat | 27 | $62,045 |
| JulucaDolutegravir/Rilpivirine | 14 | $57,080 |
| SelzentryMaraviroc | 15 | $36,525 |
| IntelenceEtravirine | 18 | $27,081 |
| Etravirine | 26 | $23,509 |
| ErtapenemErtapenem Sodium | 35 | $22,574 |
| Darunavir | 19 | $15,128 |
| EliquisApixaban | 15 | $10,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $5,786 | $527,018137 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca | $4,350 | $351,409110 claims |
| MerckIsentress | $1,176 | $141,28472 claims |
| Johnson & JohnsonPrezcobix | $1,626 | $62,04527 claims |
| PfizerSelzentry, Eliquis | $48 | $47,21330 claims |
| AbbVieSynthroid | $1,465 | $82819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.